Mirum Pharmaceuticals (MIRM)
(Delayed Data from NSDQ)
$24.80 USD
+0.02 (0.08%)
Updated May 14, 2024 04:00 PM ET
After-Market: $24.82 +0.02 (0.08%) 6:42 PM ET
3-Hold of 5 3
D Value B Growth F Momentum D VGM
Price, Consensus and EPS Surprise
MIRM 24.80 +0.02(0.08%)
Will MIRM be a Portfolio Killer in May?
Zacks Investment Research is releasing its prediction for MIRM based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MIRM
Mirum's (MIRM) Q1 Earnings & Revenues Fall Shy of Estimates
Halozyme Therapeutics (HALO) Earnings Expected to Grow: Should You Buy?
MIRM: What are Zacks experts saying now?
Zacks Private Portfolio Services
Mirum Pharmaceuticals, Inc. (MIRM) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
Mirum Pharmaceuticals (MIRM) Down 12.5% Since Last Earnings Report: Can It Rebound?
Mirum's (MIRM) Livmarli Receives FDA Nod for Expanded Use
Other News for MIRM
Mirum Pharmaceuticals, Inc. (MIRM) Q1 2024 Earnings Call Transcript
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Mirum Pharmaceuticals: Strong Buy Recommendation Amidst Resilient Performance and Promising Clinical Prospects
Positive Outlook for Mirum Pharmaceuticals with Buy Rating Amid Upcoming Catalysts and Robust Financials
Mirum Pharmaceuticals Inc (MIRM) Q1 2024 Earnings: Misses Revenue Forecasts, Posts Wider Net Loss